Soluble apps?-based gene therapy in alzheimer’s disease

The present invention relates to a method of treating Alzheimer’s disease by administration to the subject of a therapeutically effective amount of a vector which comprises a nucleic acid molecule encoding for a polypeptide which is a soluble member of the APP (amyloid precursor protein) family.

Keywords: soluble amyloid precursor protein (APPs?)
Patent Application number: European Procedure (Patents) (EPA) - 12 Juin 2015 - 15 305 904.3
Inventors:
FOL RomainBRAUDEAU JérômeABEL TobiasBUCHHOLZ ChristianMUELLER Ulrike
Publications:
Acta Neuropathol. 2016 Feb;131(2):247-266. doi: 10.1007/s00401-015-1498-9. Epub 2015 Nov 4.

Reference:

BIO15161-T1

    Business Developper
    contact
    Anne COCHI
    Business Development Manager
    Patent filling date: 12-06-2014
    Rare disease: No
    Second indication: No

    You might also be interested in